Alkermes (ALKS)
NASDAQ: ALKS
· Real-Time Price · USD
28.85
-0.15 (-0.52%)
At close: Jul 03, 2025, 3:26 PM
28.85
0.00%
After-hours: Jul 03, 2025, 04:20 PM EDT
-0.52% (1D)
| Bid | 28.79 |
| Market Cap | 4.76B |
| Revenue (ttm) | 1.51B |
| Net Income (ttm) | 352.71M |
| EPS (ttm) | 2.1 |
| PE Ratio (ttm) | 13.74 |
| Forward PE | 16.08 |
| Analyst | Buy |
| Ask | 29.5 |
| Volume | 1,113,265 |
| Avg. Volume (20D) | 2,000,758.3 |
| Open | 29.08 |
| Previous Close | 29.00 |
| Day's Range | 28.68 - 29.23 |
| 52-Week Range | 22.90 - 36.45 |
| Beta | 0.42 |
About ALKS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALKS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALKS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Alkermes is scheduled to release its earnings on Jul 23, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+6.29%
Alkermes shares are trading higher after the compa...
Unlock content with
Pro Subscription
11 months ago
+6.04%
Alkermes shares are trading higher after the company reported better-than-expected Q2 financial results.
2 months ago · seekingalpha.com
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial PossibleThe company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The on...
